| Document |
Document Title |
|
WO/2024/096121A1 |
The present disclosure provides a bacterial preparation that can be used to treat inflammatory bowel disease. More specifically, the present disclosure relates to a microorganism in which a gene from at least one of a fimbria operon gene...
|
|
WO/2024/097874A1 |
Aspects of the disclosure relate to mRNAs comprising a relatively low abundance of cytidine: adenosine (CA) dinucleotides that benefit from increased stability relative to mRNAs containing more CpA dinucleotides. The disclosure also rela...
|
|
WO/2024/095251A1 |
The present invention provides a system and a method for editing of an endogenous gene by replacing a gene portion sequence thereof comprised in a single exon with a transgene sequence, the system comprising at least one genome editing r...
|
|
WO/2024/064796A3 |
The present disclosure provides methods of treating an arrhythmogenic cardiomyopathy (ACM) in a subject. The methods generally comprise administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transfor...
|
|
WO/2024/055020A3 |
Described herein are methods for engineering proteins and viruses to improve tropism, and proteins and viruses made by using said methods.
|
|
WO/2024/096123A1 |
The present disclosure relates to the prevention of transmission and/or spread within the environment and to humans when using a bacterial preparation. More specifically, the present disclosure relates to a microorganism in which at leas...
|
|
WO/2024/093947A1 |
The present invention provides an oligonucleotide, comprising a compound of formula (Ia), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The compound of formula (I) is contained inside the oligonucleotide or at...
|
|
WO/2024/097929A1 |
Methods and materials for increasing expression of malic enzyme 1 (ME1) in T cells are provided herein, as are compositions containing ME1 coding sequences or ME1 mRNA, and methods and materials for using T cells with increased ME1 level...
|
|
WO/2024/097787A2 |
The present application provides methods and systems for improved production of cells (e.g., engineered immune cells) susceptible to fratricide. In some cases, production of engineered immune cells susceptible to fratricide that express ...
|
|
WO/2024/097602A2 |
Provided herein are composition and methods for gene therapy of LEM domain¬ containing protein 2 (LEMD2) cardiomyopathy. Viral vectors are used to deliver LEMD2 reading frame for gene augmentation in cardiac cells that harbor loss-of-fu...
|
|
WO/2024/094043A1 |
The present invention relates to a modified exosome preparation, a preparation method therefor, and use thereof. The preparation comprises: (1) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene
glycol (PEG-DSPE) at a concentr...
|
|
WO/2024/097439A1 |
A method of treating X-linked juvenile retinoschisis (XLRS) in a human subject includes subretinally delivering to the human subject a therapeutically effective amount of an rAAV vector. The rAAV vector includes a nucleic acid sequence c...
|
|
WO/2024/097861A1 |
Provided herein are methods of ameliorating a disease or disorder associated with dysregulation of the alternative complement pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
|
|
WO/2024/098063A2 |
The present disclosure describes systems and methods for accurately inserting a donor polynucleotide into a target nucleic acid locus. The systems include a programmable targeting nuclease, a transposase, and a donor polynucleotide flank...
|
|
WO/2024/093036A1 |
A method that can improve the loading efficiency of specific nucleic acid molecules in cellular exosomes and its application, which is based on the autonomous docking of multiple tandems of C/D box binding protein L7Ae or its variants to...
|
|
WO/2024/097397A1 |
Disclosed herein are polynucleotides encoding one or more ruminal-associated antigens, and polypeptides encoded by said polynucleotides. Also provided herein are compositions comprising the same, and method of making and using said compo...
|
|
WO/2024/096218A1 |
The present invention relates to a modified microorganism of the genus Corynebacterium producing L-glutamic acid and a method for producing L-glutamic acid using same, more specifically to a novel variant of nicotinamide mononucleotide t...
|
|
WO/2024/095213A1 |
The present disclosure provides nucleic acids, compositions and vectors containing and their use for effecting gene editing and/or gene expression alteration on sickle cell disease (SCD)-associated genes, e.g., in vivo. The present discl...
|
|
WO/2024/097990A1 |
Recombinant yeasts bioengineered to overexpress genes for utilization of cellulosic and hemicellulosic fibers and/or produce lipid, and methods of use thereof. The yeasts are modified to express, constitutively express, or overexpress an...
|
|
WO/2024/095037A1 |
The object of the present invention is to provide an expression platform, including a vector containing DHFR, at least one promoter, and a DNA element, such as UCOE, IRES or a combination thereof. Another object of the present invention ...
|
|
WO/2024/093843A1 |
Disclosed are a disease resistance-related protein RCR1, a coding gene thereof, and use thereof. The disease resistance-related protein RCR1 provided by the present invention is a protein set forth in sequence 2. The present invention de...
|
|
WO/2024/096738A1 |
The invention relates to nucleic acid molecules comprising a nucleotide sequence encoding a metabolic protein or a part thereof or a sequence having at least 90% sequence identity to said metabolic protein or part thereof, a human insuli...
|
|
WO/2024/094775A1 |
This document relates to engineered immune cells comprising a tumor-CAR and a FAPscFv-cytokine fusion protein with differential expressions, their use in the treatment of tumors expressing FAP, as well as methods and materials for the pr...
|
|
WO/2024/096643A1 |
The present invention relates to a method for preparing monoclonal-antibody-producing rice by using N-glycosylation mutant rice comprising a gene encoding a monoclonal antibody, and a monoclonal antibody produced thereby. In addition, a ...
|
|
WO/2024/040046A3 |
In one aspect, the disclosure relates to recombinant bacterial vectors including a gene encoding at least one antigen from Aeromonas hydrophila or tilapia lake virus, methods of making the same, vaccines incorporating the same, and metho...
|
|
WO/2024/097747A2 |
Disclosed herein are fusion polypeptides and nucleic acid encoding the same, wherein the fusion polypeptide comprises a large serine recombinase (LSR) portion and a DNA binding domain (DBD) portion.
|
|
WO/2024/096022A1 |
Provided is an anti-adiponectin antibody or an antibody fragment thereof in which LCDR1 includes an amino acid sequence of SEQ ID NO: 17 or 18, LCDR2 includes an amino acid sequence of SEQ ID NO: 19 or 20, LCDR3 includes an amino acid se...
|
|
WO/2024/044761A3 |
Methods and compositions for the production of Type 1 human milk oligosaccharides are described.
|
|
WO/2024/096790A1 |
A modular CRISPR-Cas system for ribonucleoprotein (RNP) delivery is provided, the CRISPR-Cas system comprising a CRISPR-Cas protein fused to a first binding peptide, and a functional protein fused to a second binding peptide, wherein the...
|
|
WO/2024/098035A2 |
Disclosed herein are nucleic acid molecules and compositions of preparing recombinant adeno-associated viruses (rAAV) and uses thereof. Specifically, two-plasmid systems are provided for efficient rAAV production.
|
|
WO/2024/096540A1 |
The present invention relates to a method for producing a recombinant SOD3 protein. Compared to SOD3-WT, HBD partial deletion (CKAA deletion) enables the production of SOD3 in the form of a homogeneous tetramer, can increase the expressi...
|
|
WO/2024/036303A3 |
The invention provides a modified HLA-E single chain trimer construct and nucleic acid molecules encoding thereof as well as cells and compositions comprising thereof for increasing the persistence or reducing the clearance of at least o...
|
|
WO/2024/096129A1 |
Disclosed is a biomarker for use in the prediction of the occurrence and the severity of acne vulgaris, and in the determination of the severity of acne vulgaris.
|
|
WO/2024/059543A3 |
The invention provides novel recombinant DNA, compositions, and methods for selectively regulating the expression of a transcribable polynucleotide or recombinant protein in pollen of a transgenic plant. The invention also provides trans...
|
|
WO/2024/097096A1 |
Certain embodiments of the invention provide a method of preventing or treating a B cell mediated disorder, such as B cell lymphoma and/or lupus.
|
|
WO/2024/094771A1 |
The present invention relates to a plant of the species Helianthus annuus comprising a mutant allele of a gene which encodes an endogenous FAD2-1 enzyme as well as to a cell, tissue, organ, seed, or part of a plant of the species Heliant...
|
|
WO/2024/094612A1 |
The invention relates to the treatment of a neurodegenerative diseases, via intra-putaminal route of administration, with recombinant adeno-associated viral (rAAV) particles comprising an AAV true type (AAVTT) capsid and a heterologous n...
|
|
WO/2024/097992A2 |
Provided herein are particles comprising a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors, such as lentiviral vectors, comprising the same, cells comprisin...
|
|
WO/2024/096122A1 |
The present disclosure provides a microbiome for the purpose of improving the response rate of an immune checkpoint inhibitor. Specifically, the present disclosure provides a microorganism wherein at least one gene among a flagella-formi...
|
|
WO/2024/094876A1 |
Provided herein is a messenger RNA (mRNA) comprising, from 5' to 3', a 5' untranslated region (5' UTR), at least one open reading frame (ORF), a 3' untranslated region (3' UTR), and a GC-rich sequence, wherein the mRNA comprises at least...
|
|
WO/2024/093130A1 |
The present invention provides a progesterone antibody, a preparation method, and use thereof. The progesterone antibody has a heavy chain sequence set forth in SEQ ID NO: 2, and light chain sequences set forth in SEQ ID NOs: 3-5, respec...
|
|
WO/2024/094076A1 |
Provided are a GIPR binding protein and a use thereof. Specifically provided are a single-domain antibody specifically binding to a glucose-dependent insulinotropic polypeptide receptor, a derived protein thereof, and a pharmaceutical use.
|
|
WO/2024/094084A1 |
Provided herein are engineered IscB polypeptides and IscB systems comprising the same. Provided herein are also methods and uses of using the IscB systems, including DNA cleavage and DNA base editing.
|
|
WO/2024/092904A1 |
Provided are a nucleic acid detection kit and a detection method based on a CRISPR/Cas12a system. The kit comprises a crDNA amplification primer pair, a Cas12a protein, a DNA polymerase for variable temperature amplification, an RNA poly...
|
|
WO/2024/092346A1 |
The present invention relates to an expression vector that encodes all or a portion of replicon proteins from a positive stranded virus, wherein expression of the replicon proteins is under the control of CMV and T7 promoters, and wherei...
|
|
WO/2024/097664A1 |
The present disclosure relates to compositions and methods for separating and/or purifying polyribonucleotides. The polyribonucleotide may be separated from a mixture of polyribonucleotides with a reagent that binds an aptamer on the pol...
|
|
WO/2024/095209A1 |
Provided herein are expression vectors, vector production systems, bacterial sequence- free vectors, and methods for producing adeno-associated viruses (AAVs). Also provided are AAVs as well as pharmaceutical compositions and uses thereof.
|
|
WO/2024/097314A2 |
Methods of profiling cells for donor capability with a recipient subject are provided. In particular, methods relating to identifying cells, such as T cells, suitable for making a cell therapy product and administration to a patient (e.g...
|
|
WO/2024/097979A1 |
Disclosed are nucleic acids encoding a chimeric antigen receptor comprising an extracellular domain comprising an antigen recognition domain consisting of a fully human single variable heavy (VH) domain that binds a first epitope on B-ce...
|
|
WO/2024/097608A2 |
Specific organisms derived from the gut microbiome that we have found rarely or never share homologies with tumor antigens are used to modulate bacteria-tumor antigen cross-reactive T-cells. Bacteria with low to no homologies can be safe...
|
